BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND BCL9L, BCL9-2, 283149, ENSG00000186174, DLNB11
6 results:

  • 1. The interactions of Bcl9/bcl9l with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
    Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. BCL9/bcl9l promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
    Wang X; Feng M; Xiao T; Guo B; Liu D; Liu C; Pei J; Liu Q; Xiao Y; Rosin-Arbesfeld R; Shi Y; Zhou Y; Yang M; Feng YX; Jiang Y; Shao Z; Yu K; Zhu D
    Oncogene; 2021 Apr; 40(16):2982-2997. PubMed ID: 33767438
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells.
    Mohammadi M; Salmasi Z; Hashemi M; Mosaffa F; Abnous K; Ramezani M
    Int J Pharm; 2015 May; 485(1-2):50-60. PubMed ID: 25712164
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator bcl9-2 in breast cancer Cells.
    El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
    Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The bcl9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis.
    Zatula N; Wiese M; Bunzendahl J; Birchmeier W; Perske C; Bleckmann A; Brembeck FH
    Oncotarget; 2014 Aug; 5(16):6770-87. PubMed ID: 25149534
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers.
    Toya H; Oyama T; Ohwada S; Togo N; Sakamoto I; Horiguchi J; Koibuchi Y; Adachi S; Jigami T; Nakajima T; Akiyama T
    Cancer Sci; 2007 Apr; 98(4):484-90. PubMed ID: 17309600
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.